Amgen (AMGN) Research & Development (2009 - 2026)

Amgen (AMGN) has reported Research & Development for 18 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 15.68% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.5 billion (up 22.89% YoY), while the FY2025 annual figure was $7.3 billion, up 21.93% from the prior year.
• Research & Development came in at $1.7 billion for Q1 2026 at Amgen, down from $2.1 billion in the prior quarter.
• The five-year high for Research & Development was $2.1 billion in Q4 2025, with the low at $959.0 million in Q1 2022.
• Average Research & Development over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
• Across the five-year window, Research & Development declined 21.8% in 2022 and surged 34.38% in 2024, its largest moves.
• Year by year, Research & Development stood at $1.3 billion in 2022, then rose by 15.86% to $1.5 billion in 2023, then rose by 12.39% to $1.7 billion in 2024, then advanced by 24.25% to $2.1 billion in 2025, then fell by 19.75% to $1.7 billion in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.7 billion, $2.1 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.